Reckitt Benckiser Share Discussion Threads

[yf23_1] 24/7/2017 17:03

Ridiculous rating due to search for sustainable quality. Will it survive a market shakeout because there's a long way to derate.

[sogoesit] 19/7/2017 11:53

Execution of strategy moving along nicely...

[sogoesit] 01/6/2017 13:35

WoW, 80 squid... folks like the new deal apparently.
I think I will stick my 95p back in here.

Edit 06/07: my 95p back to work at 7545p pull-back on weakness (temporary(?) fall in revenue).

[deanforester] 25/5/2017 18:03

I think that we must be at an all-time high for RB.

[sogoesit] 12/4/2017 10:54

A bit of a pop, heading for new highs.
Apparently some folks like the new deals.

95p ex-dividend tomorrow 13/04.

[bonio10000] 19/2/2017 19:27

Good.

A business (kraft) which can only grow by buying and cost stripping (UK jobs then).

No thanks.

[sogoesit] 19/2/2017 18:06

That's it; over before it began.
Kraft Offer withdrawn (Bloomberg).

[slogsweep] 17/2/2017 14:18

Has the Kraft bid for Unilever put Reckitts in play?

[sogoesit] 17/2/2017 13:59

Oops; a bid just came in for Unilever from Kraft!!
Good for our share price too.

Edit: rejected as too low at 18% premium to recent ULVR share price

[sogoesit] 12/2/2017 17:55

There seem to be a few pundits around that don't like this deal for one reason or another.
And, in general, over the years a lot of pundits have preferred Unilever over Reckitt for the reason that it is more "diversified" having food as a major part of its brand holdings. I wonder if these are the same pundits or not?
Reckitt has outperformed ULVR over the long term (5+ years) excluding dividends.
I only hold one, Reckitt, as they are highly correlated otherwise than in Reckitt's long term performance.

[philanderer] 12/2/2017 10:27

The Sunday Times: Reckitt Benckiser is facing a shareholder uprising over accusations that its $16.6 billion (£13.3 billion) deal to buy a US rival will guarantee its boss enormous future bonuses.

[philanderer] 10/2/2017 14:09

10th feb Whitman Howard buy tp 9000p
10th feb Liberum buy tp 7650p

reiterations

[deanforester] 10/2/2017 11:34

Nothing wrong with those results.

[philanderer] 06/2/2017 13:59

Reckitt Benckiser chief Rakesh Kapoor in line for £15m windfall from Mead Johnson deal

[deanforester] 03/2/2017 18:11

Looks like the Mead Johnson news helped a little. Pity that the early rise wasn't carried through.

[minerve] 02/2/2017 09:54

Maybe a bit of diversification is healthy if consumer healthcare opportunities are limited and/or too expensive. I was hoping Pfizer's consumer healthcare might come under its wing but that looks like it isn't going to happen now.

[sogoesit] 02/2/2017 08:18

Interesting move into baby foods... one of the original "Johnson & Johnson" businesses from what I read.
Looks good for the share price in any case and no equity raising.

[philanderer] 16/1/2017 18:34

16th jan Jefferies buy tp 7750p

[footrot355] 04/5/2016 12:36

Very concerned over the situation in South Korea, following on from the Australian fines, I think the BOD need to report more thoroughly on the far eastern operations.

[jdb2005] 21/2/2016 20:29

Great results for 2015 & no reason why it cannot outperform UK100 in 2016:

ommenting on these results, Rakesh Kapoor, Chief Executive Officer, said:

"RB delivered excellent growth and margin expansion in 2015 as a result of our continued focus on our Health, Hygiene and Home Powerbrand portfolio and supported by our culture of innovation and agility.

Despite a year of mixed market conditions, we achieved broad-based growth (+6% LFL), across both developed and developing markets. This was led by an exceptional performance in Consumer Health, due to both a strong flu season at the beginning of the year and outstanding performances from our innovations on brands such as Scholl, Durex, Nurofen and Strepsils.

Our virtuous earnings model continued to deliver in 2015 and resulted in significant value creation for shareholders. Strong gross margin expansion, combined with accelerated indirect cost savings from our Supercharge programme, created room in our P&L to both increase our brand equity investment (BEI) and to deliver exceptional operating margin expansion. We continue to expect Supercharge to lead to GBP150m in cost savings over three years, but have achieved a significant portion of those savings within the first year.

In 2016, we expect that the macro environment will be tough, but remain confident that our strategic choices across Powerbrands and Powermarkets will enable RB to deliver another year of growth and margin expansion. We are targeting LFL net revenue growth of +4-5%(1) . For operating margin(2) , we reiterate our medium term target of moderate margin expansion. We expect this to be supplemented in 2016 by part of the remaining Project Supercharge efficiencies."

[jdb2005] 21/2/2016 20:27

great results for 2015 & no reason it cannot continue to outperform the UK100:

ommenting on these results, Rakesh Kapoor, Chief Executive Officer, said:

"RB delivered excellent growth and margin expansion in 2015 as a result of our continued focus on our Health, Hygiene and Home Powerbrand portfolio and supported by our culture of innovation and agility.

Despite a year of mixed market conditions, we achieved broad-based growth (+6% LFL), across both developed and developing markets. This was led by an exceptional performance in Consumer Health, due to both a strong flu season at the beginning of the year and outstanding performances from our innovations on brands such as Scholl, Durex, Nurofen and Strepsils.

Our virtuous earnings model continued to deliver in 2015 and resulted in significant value creation for shareholders. Strong gross margin expansion, combined with accelerated indirect cost savings from our Supercharge programme, created room in our P&L to both increase our brand equity investment (BEI) and to deliver exceptional operating margin expansion. We continue to expect Supercharge to lead to GBP150m in cost savings over three years, but have achieved a significant portion of those savings within the first year.

In 2016, we expect that the macro environment will be tough, but remain confident that our strategic choices across Powerbrands and Powermarkets will enable RB to deliver another year of growth and margin expansion. We are targeting LFL net revenue growth of +4-5%(1) . For operating margin(2) , we reiterate our medium term target of moderate margin expansion. We expect this to be supplemented in 2016 by part of the remaining Project Supercharge efficiencies."

[ali47fish] 15/2/2016 14:00

the update said exceed targets- is the same as ahead of expectations?

[spacecake] 15/2/2016 12:18

Some good news today as seen in the share price.

[sogoesit] 27/10/2015 21:08

Yes, Minerve, looks like a break-out. More convincingly since it has broken out above a head-and-shoulders. Theoretically it should climb the height of the head from the neckline... looks like another 300-400p approx. from here at least is my guess. 6750p will also keep it within its upper rising trend channel.

RB's stated strategy "... focused on PowerMarkets and PowerBrands" suggests to me that they see more profitability (margin) in strong brands. Certainly, as a consumer I tend to buy a brand. On the online issue I don't know as our household doesnt shop for any of their stuff online.